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Sotalol is a unique beta-adrenergic blocking agent with
additional actions characteristic of Vaughn-Williams class
III antiarrhythmic agents in experimental models. To
test the efficacy of sotalol to suppress ventricular ar-
rhythmias, a 6 week parallel, placebo-controlled out-
patient study of two doses (320 and 640 mg/day, in two
divided doses) was performed in four hospitals in 56
patients with chronic premature ventricular complexes
at a frequency of 30/h or more (mean ± SE,
528 ± 60/h) on 48 hour ambulatory electrocardiographic
recording. During a placebo week, no change occurred
in arrhythmia frequency (532 ± 76/h). Subsequent so-
talol therapy significantly reduced median arrhythmia
frequency in patients receiving both low (n = 19) and
high (n = 18) doses compared with that in patients
receiving placebo (by 77 and 83%, respectively, versus
6%; p < 0.001). Twenty-two (59%) of 37 sotalol-treated
patients, 11 in each group, reached the prospectively
defined criterion of efficacy (2:75% arrhythmia reduc-
Sotalol is a unique beta-adrenergic blocking agent that ex-
hibits additional electrophysiologic effects characteristic of
class III antiarrhythmic activity (1,2). It is an old compound
that has recently been rediscovered as a potentially important
antiarrhythmic agent. Identified by Mead-Johnson Phar-
maceutical in 1960, it was developed primarily for its an-
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tion) versus 2 (11%) of 19 placebo control patients (p <
0.001). Sotalol reduced the median frequency of couplets
by 94% (p < 0.0001) and that of runs by 89% (p <
0.0007).
The electrocardiographic effects of sotalol included
reductions in heart rate (by 17 to 27%) and increases in
the QTc (by 6 to 9%) and PR (by 6%) intervals. Ejection
fraction was unchanged. The most common adverse side
effect was fatigue, but drug discontinuation was required
in only three patients taking 640 mg/day. No proar-
rhythmic events or biochemical abnormalities were
observed.
In summary, sotalol displays significant antiarrhyth-
mic activity of moderately high degree with good tol-
erance in doses of both 320 and 640 mg/day. Its anti-
arrhythmic actions are distinguished from those reported
for other beta-blockers by its effects on the QTc interval
and its moderately high degree of antiarrhythmic activity.
(J Am Coil CardioI1986;8:752-62)
tihypertensive and antianginal properties (3). It has been
clinically available as a beta-blocker for years in many coun-
tries outside the United States, including the United King-
dom (1974), France (1974), Germany (1975) and Sweden
(1979). In 1983, sotalol accounted for almost I million
prescriptions in these four countries (3).
As a beta-blocker, sotalol is noncardioselective, without
partial agonist or membrane-stabilizing activity and effec-
tively administered both orally and intravenously (3-5).
Like other beta-blockers, it has negative chronotropic and
modest negative inotropic effects. However, it is the only
beta-blocker shown to produce significant repolarization de-
lay. The 15% increase in repolarization time, consisting of
increases in refractory period and monophasic action po-
tential, has been ascribed to a separate class III antiarrhyth-
mic action (3,6).
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Renewed interest in the potential of sotalol as an anti-
arrhythmic agent has been generated by a better appreciation
of its electrophysiology (2) and by promising, although lim-
ited, recent clinical trials (7-12). Sotalol has been reported
(7,8) to be more effective than other beta-blockers in the
management of reentrant supraventricular arrhythmias, in-
cluding those utilizing a bypass tract. One recent report (9)
suggested an unusually high response rate (67%) to sotalol
in refractory sustained ventricular tachycardia induced elec-
trophysiologically. The possibility of successfully substi-
tuting sotalol for amiodarone in patients having adver se
effects from the latter has also been reported (10). Sotalol
has been appl ied with some success for secondary preven-
tion after myocardial infarction (11). It has also been re-
ported to be effective in suppressing frequent, complex ven-
tricular arrhythmias (12,13), but controlled trials to document
and quantitate this have not been performed. Thus, it was
the purpose of the present study to document the antiar-
rhythmic effectiveness of sotalol compared with placebo for
chronic , complex ventricular arrhythmia assessed by am-
bulatory electrocardiographic recordings.
Methods
The study was designed as a parallel , double-blind trial
of 6 weeks' duration in four hospitals comparing two dose s
of sotalol (160 and 320 mg twice daily) with placebo in the
treatment of chronic , complex ventricular arrhythmias that
were symptomatic or that placed the patient at increased
risk of lethal arrhythmia (14). Individual responses were
assessed by comparisons of treatment arrhythmias with those
recorded during a placebo-controlled baseline recording .
Patient eligibility and exclusion. Patient s aged 18 years
or more with premature ventricular complexes averaging
greater than 30/h on a 48 hour baseline electrocardiographic
recording and warranting treatment were candidates for the
study. Exclu sion criteria included a left ventricular ejection
fraction of less than 30%, a New York Heart Association
functional classification of IV, congestive heart failure un-
responsive to digitalis or diuretic drugs, or both, or a car-
diothoracic ratio on chest roentgenogram greater than 0.65 .
Patient s with asthma or chronic obstructive pulmonary dis-
ease requiring medication, prior severe adverse reactions to
beta-blockers, serum creatinine greater than 3 mg/dl, un-
corrected clinically significant electrolyte imbalance or un-
controlled severe hypertension (diastolic pressure ~ 120
mm Hg) were not candidates. Also excluded were patient s
with unstable angina , myocardial infarction within 3 months
and active endocarditis.
Rhythm exclusions were heart rate at rest averaging less
than 50 beats/min , sinus pauses greater than 2.5 seconds,
second or third degree atrioventricular (AV) block, sick
sinus syndrome, bundle branch block, significant supraven-
tricular arrhythmia, digitali s intoxication arrhythmia, QTc
interval greater than 0.45 second or PR interval greater than
0.24 second, rhythm requiring pacemaker or emergency
therapy and sustained ventricular tachycardia (> 30 seconds,
> 120 beats/min) or primary ventricular fibrillation. Unac-
ceptable concomitant medication included approved or in-
vestigational antiarrhythmic drugs, beta-blockers and drugs
prolonging the QT interval (for example , specific pheno-
thiazines and tricyclic antidepressants).
Institutional approval was obtained , and individual writ-
ten informed consent was required before study entry .
Patient entry characteristics. The study group con-
sisted of 58 consecutive patients showing qualifying ar-
rhythmias on screening 48 hour ambulatory electrocardio-
graphic (Holter) recordings . Two patients were withdrawn
from the study during the initial placebo control period; one
had syncope and one was lost to follow-up . The remaining
56 patient s, characterized in Table I, received blinded drug
therapy and form the basis of our report . Premature ven-
tricular complex frequency on screening evaluation aver-
aged (mean ± SE) 528 ± 60/h (range 37 to I ,945/h, median
415/h) based on a median analyzable time of 46 .2 hours
(mean 43.8). In addition, 54 patients had ventricular coup-
lets and 37 had runs of ventricular tachycardia (~3 beats).
Patients had been previously treated with an average of 2.1
agents (range 0 to 5) with inefficacy or intolerance . Entry
radionuclide left ventricular ejection fraction averaged 0.54
(range 0.25 to 0.79).
Study treatment plan. Week 1 formed the screening
baseline phase. Screening rhythm recordings , consisting of
two consecutive 24 hour ambulatory tapes (~ 1 8 of each 24
hours analyzable), had to demonstrate an average of 30 or
more premature ventricular complexes/h to qualify a patient
for study entry. Antiarrhythmic agent s were discontinued
for five or more half-lives before monitoring. Holter monitor
analysis was performed in a blinded fashion (Cardio Data
Systems) using a validated operator-interactive computer
program . Medical history , complete physical examination ,
12 lead electrocardiogram, chest X-ray film and laboratory
testing (complete blood count, urinalysis, 20 channel blood
chemistry testing [including electrolytes, creatinine, glu-
cose , bilirubin , alkaline phosphatase, aspartate aminotrans-
ferase and calcium], magne sium and creatine kinase ) were
performed. Left ventricular ejection fraction at rest was
measured by equilibrium-gated radionuclide ventriculog-
raphy .
Week 2 consisted of a placebo baseline phase that was
single-blind. Two placebo tablets were taken every 12 hours
and ambulatory rhythm recording for 48 consecutive hours
was then obtained sometime between the third and seventh
days. Interval history , cardiovascular examination and elec-
trocardiogram were obtained.
The active treatment period comprised weeks 3 to 6 and
was divided into early and final treatment phases. Patients
received a double-blind assignment, randomized in blocks
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Table 1. Patient EntryCharacteristics
No. of Age* Sex
Patients (yr) (M/F) Diagnosis LVEF*
Study group
Placebo 19 60 ± 14 12/7 CAD = 9 0.54 ± 0.11
(34 to 77) VHD = 4
HTN = I
Idio/other = 5
Sotalol, low dose 19 59 ± 15 15/4 CAD = 9 0.55 ± 0.14
(320 mg/day) (28 to 79) VHD = 2
HTN = 2
Idio/other = 6
Sotalol, high dose 18 59 ± 15 12/6 CAD = 6 0.53 ± 013
(640 mg/day) (25 to 81) VHD = 3
HTN = 4
Idio/other = 5
PVCs/h*
537 ± 502
672 ± 523
367 ± 215
Paired
Beats/ht
1.12
(0 to 164)
4.0
(0 to 369)
6.1
(0.25 to 87)
Runs/hj
0.07
(0 to 18)
0.05
(0 to 34)
0.25
(0 to 5.0)
Drug
Trials:\:
2.5
(0 to 5)
2.4
(0 to 5)
1.3
(0 to 4)
Overall 56 59 ± 14
(25 to 81)
39117 CAD = 24
VHD = 9
HTN = 7
Idio/other = 16
0.54 ± 0.12
(0.25 to 0.79)
528 ± 449
(37 to 1,945)
4.2
(0 to 369)
0.085
(0 to 34)
2.1
(0 to 5)
*Mean ± SD (range); t median (range); :\: number of antiarrhythmic drugs previously used and either ineffective or causing side effects; mean
(range). CAD = coronary artery disease; F = female; HTN = hypertension; Idio = idiopathic rhythm disorder; LVEF = left ventricular ejection
fraction; M = male; PVCs = premature ventricular complexes; VHD = valvular heart disease.
of six, to doses of 160 or 320 mg of sotalol given twice
daily (320 or 640 mg/day) or to matching placebo. Excellent
compliance was confirmed on each evaluation by history
and pill count. On day 2 of week 3 (early treatment phase),
a 24 hour rhythm recording was obtained after the morning
drug dose (that is, dose 2 or 3) to determine whether first
pass treatment effects were seen. Interval assessment was
again made at the end of week 4. During week 6 (final
treatment phase), a final (efficacy) 48 hour ambulatory rhythm
recording was obtained. Final clinical assessment was then
made, laboratory tests and electrocardiogram were obtained
and radionuclide ventriculography was repeated. The ran-
domization code was then broken and the option of long-
term open label treatment with sotalol was considered based
on clinical assessment by the investigator.
Hypotheses. A primary objective was to test the hy-
pothesis that sotalol therapy provides significant antiar-
rhythmic activity as compared in parallel with placebo ther-
apy. A secondary objective was to assess and compare the
effectiveness and tolerance of low and high dose sotalo1.
Statistical analysis of data. Average values for arrhyth-
mia frequency are generally presented as mean ± SD or
SE as noted and as median. The percent reduction in total
premature ventricular complex frequency at final treatment
versus placebo baseline phases in the placebo versus sotalol
groups comprised the primary end point. Analysis of var-
iance for repeated measures (that is, at screening baseline,
placebo baseline and early and final treatment phases) was
performed for each group (placebo and sotalollow and high
doses) by Friedman's nonparametric test for arrhythmia
variables (that is, premature ventricular complexes, paired
beats, run of beats) and by analysis of variance for heart
rate and electrocardiographic intervals. Pairwise compari-
sons were then made by Wilcoxon's test for nonparametric
and paired t test for parametric analysis, where appropriate.
Comparisons of arrhythmia response (defined for individual
patients by the ratios of frequencies during final or early
treatment and placebo baseline phases) were made among
the three groups with the Kruskal-Wallis test and subsequent
pairwise comparison, where appropriate, with the Mann-
Whitney test. Parallel comparison of other measurements
was made by analysis of variance for three groups and t test
for comparisons between two groups. Comparative assess-
ment of categorically significant responses was also made,
defined as individual decreases of 75% or greater in fre-
quency of total ventricular ectopic rhythm. Contingency
table ratios were analyzed by the chi-square test. Regression
analysis was used to test for correlations between QT, QTc,
AQT or AQTc intervals and arrhythmia response. A prob-
ability (p) value of less than 0.05 (two-tailed hypothesis)
was regarded as significant.
Results
Comparison of baseline characteristics (Table 1).
Baseline characteristics of patients randomly assigned to the
placebo and the two sotalol groups were similar (Table 1).
Premature ventricular complex frequency at screening base-
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line was not significantly different among groups , averaging
524 ± 70/h (mean ± SE) in sotalol-treated versus 537 ±
115/h in placebo-treated patient s . Left ventricular ejection
fraction was also similar (mean ± SD 0.54 ± 0.11 versus
0.54 ± 0 .13, respectively). Occurrence of repetitive pre-
mature beats (couplets, runs) was variable , but differences
were not significant.
Efficacy Results: Response of Premature Ventricular
Complexes (Table 2, Fig. 1 to 3)
Significant time (treatrnenn-related changes in total fre-
quency of premature ventricular complexes were observed
for low (p < 0.0001) and high (p < 0 .0001) dose sotalol-
treated but not for placebo-treated patients (p = 0.13). Also,
individual responses (final treatment versus placebo base-
line) differed significantly among groups (p < 0.0005).
Placebo baseline period. Arrhythmia frequency was un-
affected during the placebo baseline period, averaging
532 ± 76/h (mean ± SE), compared with that of the screen -
ing baseline evaluation (528 ± 60/h) . Frequency was
510 ± 123/h for those in the placebo group and 543 ±
98/h for the sotalol group (p = NS).
Treatment periods. Final treatment phase. At the final
efficacy end point (week 6), patients receiving sotalol ex-
perienced a median individual reduction in premature ven-
tricular complexes of 77.9% (range 100 to < - 100%
suppression) (Table 2) . The mean percent reduction , ex-
cluding values for one outlier, was 62.6 ± 41.6%
(mean ± SD). For low dose sotalol (320 mg/day) , the
median response in individual reductions was 77.3% (Fig .
2) and for high dose therapy (640 mg/day) it was 83.0%
(p = NS) (Fig. 3). In contrast, for placebo, median response
was only a 6.2% reduction (mean - 18.1% [increase], range
+87 to - 249% suppression; p = NS) (Fig. I, Table 2).
Individual responses to therapy differed among the three
groups in a highly significant fashion (p < 0.0005). Dif-
ferences were observed comparing all sotalol-treated pa-
tients or each subgroup with placebo -treated patients (p <
0 .001 for each), but the small difference in response between
the two drug doses was not significant (p = 0.42).
Twenty-two (59%) of 37 sotalol-treated patients , II in
each dose group, versus 2 (I 1%) of 19 placebo-treated pa-
tients achieved the defined level of therapeutic success (2:75%
premature ventricular complex reduction ) (p < 0.001). (Av-
erage suppression among the 22 responders was 87%.) Only
one patient (Case 38) showed an increase in isolated (but
not repetitive) premature ventricular complexes suggestive
of a possible proarrhythmic effect (15) . However, this re-
sponse appeared to be due largely to an inordinate spon-
taneou s reduction in arrhythmia (96%) during the placebo-
baseline period.
The frequency of premature ventricular complexes de-
creased 58% overall in the low dose sotalol group (mean ±
SE, 648 ± 174 to 274 ± 76/h , P < 0.002), 67% in the
high dose sotalol group (433 ± 80 to 142 ± 39/h , p =
0.001), but only 18% in the placebo group (510 ± 123 to
419 ± 95/h, P = 0.52).
Early treatment phase . Smaller" but still significant in-
dividual reductions in total arrhythmia frequency were noted
during early treatment (first pass) assessment: 56% median
(36% mean) reductions for sotalol patients versus 12% me-
dian ( - 6% mean) reductions for placebo patients (p <
0 .001 for sotalol versus placebo). Overall , frequenc y of
premature ventricular complexes decreased 41% in the low
dose group (to 382 ± 117/h, P < 0.004), 57% in the high
dose group (to 186 ± 67/h, p < 0.001), but only 7% in
the placebo group (to 476 ± 107/h) .
Efficacy Results: Response of Repetitive Beats
(Table 2)
Response of coupled beats. Significant time (treat-
mentj-related changes in frequency of coupled beats were
observed for low (p < 0 .0002) and high (p = 0.0014) dose
sotalol-treated but not for placebo -treated patients (p =
0.35) . Also, individual responses for the late treatment phase
differed significantly among groups (p < 0.03) . Median
individual suppression of couplets during sotalol adminis-
tration was 91%. Overall, frequency of coupled beats was
suppressed by a median of 94% (p < 0.001 , all sotalol
patients). Response was similar for the two drug doses .
In the low dose group , the median frequenc y of beats in
pairs was 2.21h(mean 67.6/h) during placebo-baseline, 0.61/h
(mean 17.2/h) during early therapy and 0.40/h (mean 6.8/h)
during final therapy assessments . Overall , coupled beats
decrea sed by a median of 72% (mean 75%) at early (p =
0 .09) and 81% (mean 90%) at final (p = 0.002) therapy
assessment. Individual reductions exceeded 90% in 10 of
18 patients with baseline couplets; the median individual
response was 90.3% suppression (p = 0.01 versus placebo) .
In the high dose group , the median frequency of beats
in pairs was 1O.1Ih (mean 19.7/h) during placebo-baseline,
0.78/h (mean 3.27/h) during early therapy and 1.23/h (mean
6.60/h) during final therapy assessments. Overall , coupled
beats decreased by a median of 92% (mean 83%) at early
(p = 0.001) and 88% (mean 66%) at final (p < 0 .02)
treatment assessments . Reductions exceeded 90% in 9 of
16 patients with baseline couplets; the median individual
response was 91.4% suppression (p = 0.04 versus placebo) .
In the placebo group. the median frequency of beats in
pairs was 1.46/h (mean 28.4/h) during placebo-baseline ,
O.93/h (mean 33.8/h) during early therapy and 2.36/h (mean
13.8/h) during final therapy. The median individual suppre s-
sion was only 17.8% among the 16 patients with baseline
couplets .
Response of runs of ventricular premature complexes.
Baseline run frequency was generally low and variable,
precluding significant comparisons in response over time
and among groups. For the combined groups of all sotalol-
Table 2. Individual Patient Efficacy Data
Hourly PYCs/Cp BeatslRun Beats
Group (dose) and Placebo-Baseline Early Treatment Final Treatment %A PYCs
Patient No. * (week 2) (week 3) (week 6) (week 6 vs. 2)
Placebo
1 161/1.1/0 10510/0 4710.04/0 -71
4 700171/5.4 950178/4.8 9211.7/0.23 -87
7 75/0.77/0.02 189/3.010 262/9.4/0.80 +248
8 1,444/0.0810 1.1281010 1.2211010 -15
16 124/0.9110 3610.5110 267/0.26/0 + 115
17 569/010 258/0/0 NAt -55
20 139118/5.7 264/13/8.1 312/31/3.5 + 125
24 1371010 9910/0 34/010 -75
28 1781010 2731010 3.8510.09/0 + 116
29 470/39/24 308/35/2.7 235/2.410.58 -50
33 662/120/46 9741119/66 621/119/17 -6.2
35 257/2012.2 419175/8.1 426122/40 +66
40 4010.31/0 2910.9310 32/1.010.13 -19
41 l, 150/1.810.44 1,13410.0910.44 1,532/2.3/0.70 +33
46 (217):j:/(I.I)/(0.06) 17310.34/0 254/0.85/0 +17
47 18010.63/0 166/0.7210 316/4.7/0.07 +76
49 1,8751171117 1,658/250/31 827/29/3.9 -56
51 231/4.7/1.1 250/5.410.13 313/8.010.65 +36
58 784/6312.3 629/59/6.1 36911611.4 -53
Sotalol, low dose (320 rng/day)
2 343/13/4.5 4010.13/0.10 246/4016.3 -28
5 966/168/5.7 1,375/82/0.31 997/21/4.1 +3.3
10 419/0.64/0 181/6.6/0 6010.0510 -86
II 261/6.5/1.4 41311.110.36 9.8/0.63/0.17 -96
13 800/139192 275/8.5/66 138/4.8/1.0 -83
18 288/4811. 9 27715412.9 35/0.2310.09 -88
19 238/0.69/0 311010 62/0/0 -74
23 13312.210 2110.16/0 3,010.5710.17 -77
25 2,438/0.04/0 1,099/010 9401010 -6\
26 101/1.7/0.57 2510.59/0.38 14/0.3010.11 -86
32 2,8611505170 1,828/86/5.6 616/3.010.06 -79
36 769/379/81 296/2513.3 411/57/5.3 -47
38 18§10/0 631010 852§10.4010 +4,515
42 217/0.73/0 116/0.09/0 5410.48/0 -75
43 276/0.16/0 01010 215/0.13/0 -22
44 472114/0.13 548152/0.13 9910.09/0 -79
53 832/0.61/0.07 4.8/010 184/0/0 -78
55 255/4.110.22 153/0.61/0 1.3/0.04/0 -99.5
56 625/1.010.54 512/1110 249/0.7710 -60
Sotalol, high dose (640 mg/day)
3 442112/1.8 11317 .5115 110/0.29/0 -75
6 8910.1710 NA 7.01010.14 -92
9 577117/2.0 NA 75/0.2110 -87
12 997/87/33 940/6.310.75 181/2210.38 -82
14 8610.34/0 258/0/0 8.81010 -90
15 13218.010.39 78/0.5110.13 257/1.310.34 +96
21 805/2310.57 55211010.30 630/26/2.4 -22
22 150/010 122/4.6/1.4 5813.110.47 -61
27 275/39/22 5115.9/0 01010 -100
30 229/26/2.1 NA 204/2.2/0.20 -II
31 318/8.411 .4 6710.0810 12/0.13/0.06 -96
34 643/25/5.3 75/0.7810 424113/4.6 -34
37 825114/2.7 24/0.76/0.34 7811.2/0.15 -91
39 824/0.58/0.07 7514.4/0.56 29/2.610.36 -97
45 178/6.310.65 93128/0 223/4410.76 +25
48 6.2/010 4.41010 0.11/010 -98
54 1,001180119 36917.010 12710.29/0 -87
57 204/8.010.14 2910.5810.16 127/1.5/0.15 -38
*Patients 50 and 52 were withdrawn before week 3. tData not available; recording faulty; week 3 used for
efficacy estimate. :j:Week 1 used as baseline; recording faulty for week 2. §Baseline (week I) frequency was
477/h. Cp Beats = beats in couplets; NA = not available; PYCs = premature ventricular complexes; run
beats = beats in runs of ventricular tachycardia (2:3 beats).
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Figure I. Individual percent suppression in av-
erage hourly total frequency of premature ventric-
ular complexes (PYC) in placebo-treated patients.
comparing final treatment with placebo-baseline
phases. Patient entry number is given in parenthe-
ses. Level defined as showing antiarrhythmic effi-
cacy (75%) is indicated by dashed lines.
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treated patients, the frequency of beats in runs (2::3 beats/run)
was suppressed with sotalol by a median of 89% at final
therapy (p < 0.007). Response was similar for the two
doses.
In the low dose group, the median frequency of run events
was 0.05/h (mean 3.9/h) during placebo-baseline, O/h (mean
OAO/h) during early therapy (p = 0.01) and O/h (mean
OAI/h) during final therapy assessments (p = 0.02). In
parallel with run events, the number of beats in runs de-
creased by a median of 100% (mean 93%) from a median
of 0.22/h (mean 13.6/h) during placebo-baseline to O/h (mean
0.9I/h) at the end of drug therapy (p = 0.02).
In the high dose group. the median frequency of runs
was 0.33/h (mean 1.6/h) during placebo-baseline, 0.04/h
(mean O.08/h) during early (p < 0.0 I) and 0.005/h (mean
O.16/h) during final (p < 0.04) therapy evaluations. In par-
allel with run events, the number of beats in runs decreased
by a median of 85% (mean 89%), from a median of 1.0/h
(mean 5.1) during placebo-baseline to 0.15/h (mean 0.55/h)
at the end of drug therapy (p < 0.04). The median individual
reduction was 93% among the 14 patients with baseline
runs.
In the placebo group, the median frequency of runs was
low at baseline, 0.09/h (mean I. 71/h) (eight had no runs),
and was O.l7/h (mean 0.54/h) at the end of therapy. The
median number of beats in runs was O.23/h (mean 5.8/h)
during initial placebo and OA5/h (mean 3.8/h) during final
therapy (p = NS).
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Figure 2. Individual percent suppression in av-
erage hourly frequency of premature ventricular
complexes (PYC) in low dose sotalol-treated pa-
tients (320 rug/day), comparing final treatment with
placebo-baseline phase. Format similar to that of
Figure I.
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Figure 3. Individual percent suppression in av-
erage hourly total frequency of premature ventric-
ular complexes (PVC) in high dose sotalol-treated
patients (640 mg/day), comparing final treatment
with placebo-baseline phase. Format similar to that
of Figure 1.
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Electrocardiographic, Ventriculographic and Blood
Pressure Effects (Table 3)
Electrocardiogram. The major effects of sotalol on the
electrocardiogram at final therapeutic assessment included
a slowing of the sinus rate and an increase in the QTc
interval. Placebo had no effect. Heart rate on 12 lead elec-
trocardiogram decreased by 26% with low dose and by 27%
with high dose sotalol (both p < 0.001). Average heart rates
on ambulatory monitor recordings decreased by 17% with
Table 3. Electrocardiographic and Ventriculographic Changes*
Placebo-Baseline Versus Final Treatment Comparison
Placebo
Sotalol (320
mg/day)
Sotalol (640
mg/day)
Placebo Drug Placebo Drug Placebo Drug
Electrocardiographic intervals
Heart rate (beats/min) (Holter)
Mean 80 81 75 62§** 75 56t**
SO 12 12 9 7 9 6
Heart rate (beats/min) (ECG)
Mean 76 76 72 54§** 71 52§**
SO 12 13 9 7 13 7
PR (ms)
Mean 179 180 172 189§ 182 188
SO 30 33 49 53 42 39
QRS (ms)
Mean 89 88 89 86 89 89
SO 17 20 26 20 14 16
QT (ms)
Mean 372 377 380 467§** 388 499§**
SO 38 42 37 45 30 78
QTc (ms)
Mean 429 419 416 440*11 421 460t~
SO 25 27 41 35 28 52
Ejection fractiontt
Mean 0.54 0.50t 0.55 0.56 0.53 0.59
SO 0.11 0.09 0.14 0.12 0.13 0.10
*On paired samples. tp < 0.05 versus predrug placebo; tp < 0.01; §p < 0.001 (paired t test); lip < 0.05
versus parallel placebo; ~p < 0.01; **p < 0.001 (unpaired t test);ttdetermined by radionuclide ventriculography,
for the left ventricle. ECG = electrocardiogram.
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low doses and 25% with high doses of the drug (both p <
0.00 I) . The parallel comparison of drug with placebo heart
rate at the final therapy evaluation was also highly significant
(p < 0.001). The PR interval increased slightly (+ 6%) with
sotalol (p < 0.00 I); no consistently greater effect was noted
in those with an initial PR interval greater than 0.20 second.
No changes in QRS duration occurred. The QT interval
increased by an average of 87 ms ( + 23%) during low dose
(p < 0.001) and 110 ms (+ 29%) during high dose (p <
0 .001) sotalol therapy. The corrected QT (QTc) interval
increased by an average of 24 ms ( + 6%) during low dose
(p < 0 .01) and 40 ms (+9%) during high dose (p < 0.001)
therapy . The differences in QT and QTc responses between
low and high doses of sotalol were not significant. Parallel
comparisons of sotalol with placebo group QT (p «; 0.001)
and QTc (p < 0.01) intervals were significant. No corre-
lation could be established between individual changes in
QTc interval duration and arrhythmia reductions. Interval
electrocardiographic changes were mostly established at early
therapy: heart rate decreased by 22% (p «; 0.001) ,
the PR interval increased by 5% (p < 0 .02) and the QTc
interval increased by 7% (+30 ms) (p < 0.001).
Ejection fraction. Radionuclide left ventricular ejection
fraction was not adversely affected by sotalol therapy. Ejec-
tion fraction averaged 0 .54 ± 0.11 (mean ± SO) before
and 0.58 ± 0.11 at late therapy in sotalol-treated patients
(p = NS) and 0.54 ± 0.13 before and 0.50 ± 0.09 after
therapy in placebo-treated patients (p = 0.03). Among so-
talol-treated patients with an ejection fraction of less than
0.50, none showed a decrease greater than 0.05 .
Blood pressure. Sotalol had a modest antihypertensive
effect. Blood pressure (mean ± SO) decreased from
130 ± 12/76 ± 10 mm Hg (placebo) to 121 ± 18/69 ±
8 mm Hg (final therapy} (one center, n = 25). The change
in diastolic pressure was significant (p < 0.005). Placebo
had no effect on blood pressure: 130 ± 19/73 ± 12 to
131 ± 24174 ± 14 mm Hg.
Adverse Effects
Adverse symptoms. These were common but mostly
minor during treatment (weeks 3 to 6), being reported by
11 patients (58%) in the placebo, 14 (74%) in the low dose
and 16 (89%) in the high dose groups (p = NS). The number
of complaints per patient was similar among groups: 2.0
for placebo, 1.5 for low dose and 1.8 for high dose therapy .
Common complaints during high dose drug therapy included
fatigue (II patients), slow heartbeat (6 patients) , chest dis-
comfort (4 patients), dizziness/light-headedness (4 patients)
and (exertional) dyspnea (3 patients) . Complaints during
low dose sotalol therapy were similar, including fatigue (II
patients), light-headedness (5 patients) and slow heart rate
(4 patients) . Among the 11 placebo-treated patients with
symptoms, these were dizziness/light-headedness (8 pa-
tients), fatigue (7 patients), palpitation (6 patients), chest
pain (3 patients), bloating (3 patients) and anxiety (2 pa-
tient s) . Fatigue, common to all groups. appeared to be of
somewhat greater subjective severity in the sotalol group .
Three patients , all in the sotalol high dose group, had to
discontinue therapy because of excessive symptoms (fa-
tigue , bradycardia, chest pain) . Efficacy was finally assessed
and the drug was then discontinued in these three patients
on days 5 to 7.
Adverse rhythm and laboratory effects. Although QT
and QTc intervals lengthened, no clinically significant
proarrhythmic events (for example, torsade de pointes or
sudden death) occurred. No significant laboratory abnor-
malities, potentially ascribable to sotalol, were observed.
Discussion
Summary of study findings. The present study has dem-
onstrated in a controlled fashion the substantial activity of
sotalol against chronic, complex ventricular arrhythmias: 22
sotalol-treated patients (59%) versus only 2 placebo-treated
patients (11%) were clinical responders (2::75% suppres-
sion). Antiarrhythmic activity was greater against repetitive
beats (couplets, runs) (>90% median reductions) than against
isolated beats (78% median reduction) . As expected, sotalol
also reduced heart rate and increased QTc and PR intervals.
The efficacy and QT effects tended to be greater with the
higher dose but not significantly so, and no correlation be-
tween individual QTc change (which was quite variable)
and antiarrhythmic effect could be made. Tolerability of the
lower dose was good and that of the higher dose was fair.
Reported symptoms were typical of those expected with
beta-blockade. Depression of left ventricular function or
overt heart failure was not observed in this relatively stable
patient population.
It should be emphasized that the results of this study
cannot be applied to patient groups with sustained ventric-
ular tachycardia or ventricular fibrillation or to those with
more severe structural heart disease (ejection fraction < 30%)
and complex ventricular arrhythmias.
Previous comparative animal studies. Patterson et al.
(16) showed d.l-sotalol to possess antiarrhythmic and an-
tifibrillatory actions in the postinfarction ischemic canine
heart . Ventricular refractory period was increased (by 35
ms) and sustained ventricular arrhythmia could no longer
be induced in eight of eight animals 4 to 7 days after in-
farction following administration of sotalol, 8 mg/kg (non-
sustained arrhythmia was induced in three) . In a conscious
canine model of ischemia-induced ventricular fibrillation,
sotalol decreased the incidence of ventricular arrhythmia
and increased survival from 7 to 65% (p < 0.001) (16). In
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separate dog experiments (17-19), both d.l- and d-sotalol,
as well as other beta-blockers, were shown to elevate the
electrical threshold for induction of ventricular fibrillation.
Cobbe et al. (20) compared the activity of sotalol and
metoprolol on reentrant ventricular tachyarrhythmias in con-
scious dogs in the late postmyocardial infarction period.
Electrically induced ventricular arrhythmias were prevented
or significantly slowed in 58% (II of 19) of sotalol studies
compared with 7% (I of 14) of metoprolol studies. Sotalol
but not metoprolol substantially prolonged infarct zone re-
fractoriness.
Previous human efficacy trials on supraventricular
arrhythmia. Sotalol has shown substantial promise in the
treatment of supraventricular arrhythmias. Teo et al. (7)
used sotalol injections or infusions to treat supraventricular
tachyarrhythmias in 29 patients: sinus rhythm was obtained
in 100% of cases of paroxysmal supraventricular tachycar-
dia, 86% of cases of atrial flutter and 33% of cases of atrial
fibrillation when infusions were used. Rizos et al. (8) found
sotalol to be more effective than metoprolol, preventing
induction of sustained supraventricular tachycardia in 59%
of 17 patients versus the 24% rate of prevention achieved
with metoprolol (p < 0.05). Sotalol increased refractoriness
in both the atrium and the ventricle to a greater extent than
did metoprolol. Only sotalol lengthened the anterograde
effective refractory period in patients with extranodal ac-
cessory tracts.
Human efficacy trials in ventricular arrhythmia. Early
trials suggest that sotalol may also represent an important
addition to the therapy of ventricular tachycardia. Sotalol
prevented electrophysiologic induction of sustained tachy-
cardia in 12 of 18 patients studied by Senges et al. (9).
Intravenous sotalol (1.5 mg/kg) prevented induction of ven-
tricular tachycardia in three of eight patients studied by
Nademanee et al. (21). These early results in groups with
more malignant ventricular arrhythmias than those of our
population are of substantial interest and suggest more ex-
tensive future evaluation.
The effect of sotalol on chronic premature ventricular
complexes has not previously been thoroughly studied.
Burckhardt et al. (12) evaluated a dose of 320 mg once
daily and placebo in a 2 week study in 14 patients with
ischemic heart disease. The mean total number of premature
ventricular complexes decreased 58%, from 4,972 to 2,904
(p = NS), and their complexity also decreased and corre-
lated with QTc interval changes. In a provocative report,
Burckhardt et al. (10) successfully substituted sotalol for
amiodarone, a class III antiarrhythmic agent with significant
long-term toxicity, in six of seven patients. In a preliminary
report, Wang et al. (13) described a small dosing trial of
sotalol (160 to 960 mg/day) in 10 patients with stable ven-
tricular arrhythmia. Although side effects prevented study
completion in three patients (torsade de pointes in one),
efficacy (>70% arrhythmia suppression) could be demon-
strated in six of the seven others. Sotalol was observed to
cause increases in the QTc interval at plasma concentrations
higher than those producing substantial beta-blockade; three
of six patients required such higher concentrations for ar-
rhythmia suppression. Our study, demonstrating moderately
high activity of sotalol against ambulatory ventricular ar-
rhythmias, confirms the impression of relative efficacy de-
rived from these previous trials.
Recently, a favorable comparison of sotalol with pro-
cainamide appeared. Lidell et al. (22) performed an open,
randomized, crossover trial in 33 patients with chronic pre-
mature ventricular complexes. With titration of sotalol (160
to 640 mg/day) or procainamide (3 to 4.5 g/day) until pre-
mature ventricular complexes were controlled (>75% re-
duction), maximal dosage was reached or adverse effects
appeared, sotalol proved efficacious in 22 patients (67%)
and procainamide in 13 patients (39%).
Electrophysiologic/electrocardiographic effects. So-
talol has consistently caused prolongation of cycle length,
AV node conduction, QT interval and cardiac refractoriness
in both animal and human studies (3). Echt et al. (23)
compared the electrophysiologic effects of sotalol and pro-
pranolol; sotalol prolonged the atrial and ventricular effec-
tive refractory periods and lengthened monophasic action
potential duration, repolarization and QT interval but pro-
pranolol did not. Nathan et al. (24) observed prolongation
of atrial, ventricular and AV node effective refractory pe-
riods after intravenous sotalol in 24 patients with Wolff-
Parkinson-White syndrome; about half also showed in-
creases in accessory pathway refractoriness. Other studies
(13) showed beta-blockade to occur at lower doses and QT
prolongation to be dose-dependent within the commonly
used range. Antiarrhythmic efficacy, however, was not con-
sistently correlated with changes in QT interval (12,13).
The electrocardiographic effects of sotalol in our study are
similar to those observed by others: greater QT interval
prolongation but little additional slowing in heart rate oc-
curred at the higher dose; efficacy could not be clearly
related to QT interval change.
Adverse potential. In this study and previous studies
(3), side effects typical of beta-blockade (such as fatigue)
were noted with sotalol, occurring with a net incidence ratio
of about 10 to 20%. Case reports of congestive heart failure
have also appeared (9). Of greater concern have been case
reports of proarrhythmiceffects, specificallytorsade de pointes
(polymorphic ventricular tachycardia with QT prolonga-
tion). McKibbin et al. (25) presented 13 patients treated
with sotalol (median dose 320 rug/day, range 80 to 480
mg/day) who developed syncope and a prolonged QTc in-
terval. Criteria for torsade de pointes were present in 10.
Hypokalemia was frequent (n = 8), often ascribed to com-
bination therapy with hydrochlorothiazide (as Sotazide in
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12 patients); combination therapy with other drugs known
to prolong QT interval was also common (n = 5). Recovery
occurred after drug discontinuation and electrolyte repletion
in all. We did not see torsade de pointes in our relatively
small series despite QT prolongation, but serum potassium
levels were carefully guarded.
Is d,l-sotalol a unique beta-blocking antiarrhythmic
agent? The significance of additional class III activity to
the antiarrhythmic effects of sotalol remains to be clearly
defined (2). In our study, the moderately high therapeutic
efficacy of sotalol for ventricular arrhythmia appears to ex-
ceed that of other commonly tested beta-blockers without
class III action and to be comparable with that expected for
potent class I antiarrhythmic agents (21,26). Our study can-
not separately assess class III and class II actions, which
must await comparative trials among d, l-sotalol, d-sotalol
and standard beta-blockers. The lack of a clear correlation
of QT interval (class III) change with antiarrhythmic effect
indicates a complex explanation for the effectiveness of
sotalol on an individual basis.
Ventricular antiectopic activity may be a relatively poor
measure of class III action (27,28). As reviewed earlier,
sotalol appears to possess greater effects than other beta-
blockers for the treatment of supraventricular tachyarrhyth-
mias and probably for inducible, sustained ventricular tach-
yarrhythmias (7-9). Although both d- and d,l-sotalol pre-
vent sudden death from ventricular fibrillation in conscious
canine models (16), they have not been shown to be superior
to other beta-blockers in reducing cardiac mortality in post-
myocardial infarction trials (11).
Future studies will be of interest, including trials with d-
sotalol, which appears to possess class III but not class II
activity. These trials will undoubtedly be useful in better
defining the potential therapeutic contribution of this inter-
esting and promising antiarrhythmic drug.
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